MCID: ESP025
MIFTS: 39

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 44 72
Oesophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 44 C562730
NCIt 50 C4025
UMLS 72 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to barrett esophagus and adenocarcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Colorectal Cancer Metastasis and MicroRNAs in cancer. The drugs Cisplatin and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and testes, and related phenotype is digestive/alimentary.

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 barrett esophagus 30.7 TP53 PTGS2 ERBB2
2 adenocarcinoma 30.1 TP53 SMAD4 PTGS2 HNF1A-AS1 ERBB2
3 peptic esophagitis 30.0 ATP4A ATP12A
4 barrett's adenocarcinoma 29.9 TP53 PTGS2 ERBB2
5 gastric adenocarcinoma 29.9 TP53 SMAD4 PTGS2 ERBB2
6 hernia, hiatus 29.8 ATP4A ATP12A
7 familial adenomatous polyposis 29.6 TP53 SMAD4 PTGS2
8 squamous cell carcinoma 29.1 TP53 SMAD4 PTGS2 HNF1A-AS1 ERBB2
9 esophageal cancer 29.0 TP53 SMAD4 PTGS2 MIR21 ERBB2
10 bile reflux 28.8 PTGS2 ATP4A ATP12A
11 active peptic ulcer disease 28.8 PTGS2 ATP4A ATP12A
12 gastric cancer 26.7 TP53 SMAD4 PTGS2 MIR215 MIR21 MIR145
13 colorectal cancer 26.2 TP53 SMAD4 PTGS2 MIR215 MIR21 MIR145
14 gastric papillary adenocarcinoma 10.7 TP53 ERBB2
15 pleomorphic adenoma carcinoma 10.7 TP53 ERBB2
16 non-proliferative fibrocystic change of the breast 10.7 TP53 ERBB2
17 uterine corpus serous adenocarcinoma 10.7 TP53 ERBB2
18 mutyh-associated polyposis 10.7 TP53 SMAD4
19 breast squamous cell carcinoma 10.7 TP53 ERBB2
20 uterine body mixed cancer 10.6 TP53 ERBB2
21 microglandular adenosis 10.6 TP53 ERBB2
22 glioma susceptibility 1 10.6 TP53 ERBB2
23 endocrine gland cancer 10.5 TP53 SMAD4 ERBB2
24 breast adenocarcinoma 10.4 TP53 SMAD4 ERBB2
25 uterine corpus cancer 10.4 TP53 ERBB2
26 thoracic benign neoplasm 10.4 TP53 ERBB2
27 tongue squamous cell carcinoma 10.3 TP53 MIR21 AFAP1-AS1
28 breast benign neoplasm 10.3 TP53 ERBB2
29 leukemia, chronic lymphocytic 2 10.2 TP53 MIR145 MIR143
30 helicobacter pylori infection 10.2
31 protoplasmic astrocytoma 10.2 TP53 PTGS2
32 dysphagia 10.2
33 recurrent respiratory papillomatosis 10.2 TP53 PTGS2
34 cardia cancer 10.2
35 neutropenia 10.2
36 fungal esophagitis 10.1 ATP4A ATP12A
37 gastroduodenal crohn's disease 10.1 ATP4A ATP12A
38 diclofenac allergy 10.1 ATP4A ATP12A
39 neonatal candidiasis 10.1 ATP4A ATP12A
40 ovarian serous carcinoma 10.1 MIR21 MIR145 MIR143
41 squamous papillomatosis 10.1 ATP4A ATP12A
42 gastritis 10.1
43 gastrointestinal neuroendocrine benign tumor 10.1 ATP4A ATP12A
44 aspiration pneumonitis 10.1 ATP4A ATP12A
45 toxic megacolon 10.1 ATP4A ATP12A
46 granulomatous gastritis 10.1 ATP4A ATP12A
47 gastric antral vascular ectasia 10.1 ATP4A ATP12A
48 acute laryngitis 10.1 ATP4A ATP12A
49 laryngitis 10.1 ATP4A ATP12A
50 gastric neuroendocrine neoplasm 10.1 ATP4A ATP12A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.1 ATP12A ATP4A ERBB2 PTGS2 SMAD4 TP53

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Dexlansoprazole Approved, Investigational Phase 2, Phase 3 103577-45-3, 138530-94-6 9578005
7
Theophylline Approved Phase 2, Phase 3 58-55-9 2153
8
Lansoprazole Approved, Investigational Phase 2, Phase 3 103577-45-3 3883
9 Antineoplastic Agents, Immunological Phase 3
10 Tubulin Modulators Phase 3
11 Antimitotic Agents Phase 3
12 Pharmaceutical Solutions Phase 3
13 Albumin-Bound Paclitaxel Phase 3
14 Antineoplastic Agents, Phytogenic Phase 3
15 Neurotransmitter Agents Phase 2, Phase 3
16 Gastrointestinal Agents Phase 2, Phase 3
17 Antacids Phase 2, Phase 3
18 Purinergic P1 Receptor Antagonists Phase 2, Phase 3
19 Respiratory System Agents Phase 2, Phase 3
20 Peripheral Nervous System Agents Phase 2, Phase 3
21 Phosphodiesterase Inhibitors Phase 2, Phase 3
22 Anti-Asthmatic Agents Phase 2, Phase 3
23 Proton Pump Inhibitors Phase 2, Phase 3
24 Anti-Ulcer Agents Phase 2, Phase 3
25 Vasodilator Agents Phase 2, Phase 3
26 Autonomic Agents Phase 2, Phase 3
27 Bronchodilator Agents Phase 2, Phase 3
28
Epirubicin Approved Phase 2 56420-45-2 41867
29
Trioxsalen Approved Phase 2 3902-71-4 5585
30
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
33
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
34
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
35
Lenograstim Approved, Investigational Phase 2 135968-09-1
36
Melphalan Approved Phase 2 148-82-3 460612 4053
37
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
38
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
39
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
40
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
41
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
42
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
43
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
44
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
45
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
46
Fluorouracil Approved Phase 2 51-21-8 3385
47
leucovorin Approved Phase 2 58-05-9 143 6006
48
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
49
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
50
Pancrelipase Approved, Investigational Phase 2 53608-75-6

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
2 A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
3 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
4 A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer Completed NCT00003118 Phase 3 cisplatin;fluorouracil
5 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
6 A Randomized Trial Comparing Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain Recruiting NCT03319121 Phase 2, Phase 3 Empirical therapy group;Guided therapy group
7 Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
8 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer Unknown status NCT00003326 Phase 2 paclitaxel
9 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma. Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
10 Esophageal Cancer: A Phase II Study of Paclitaxel, Carboplatin and 5-Fluorouracil With Simultaneous Radiotherapy Followed by Surgical Resection Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
11 Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal Esophagus Unknown status NCT00865982 Phase 2 Docetaxel, Cisplatin, Capecitabine
12 Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
13 Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan
14 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
15 A Phase II Study of Neoadjuvant Therapy With Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of the Distal Esophagus Completed NCT00757172 Phase 2 cisplatin;docetaxel
16 A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus Completed NCT00165191 Phase 2 Doxorubicin;Cisplatin;5-fluorouracil
17 Phase II Single-Arm Trial Of CPT-11 (Irinotecan HC1; Camptosar Injection)/Cisplatin In Patients With Advanced Esophageal Cancer Completed NCT00030862 Phase 2 cisplatin;irinotecan hydrochloride
18 Gemcitabine Plus Irinotecan in Patients With Esophageal Cancer, Phase II Completed NCT00012363 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
19 Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer Completed NCT00006245 Phase 2 alvocidib;paclitaxel
20 A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach Completed NCT00985192 Phase 2 everolimus
21 A Phase II Multicenter Study of the Efficacy and Safety Study of PNU-93914 (Liposome Encapsulated Paclitaxel) in Patients With Advanced Esophageal Cancer Previously Exposed to Chemotherapy Completed NCT00016900 Phase 2 liposomal paclitaxel
22 Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer Completed NCT00005599 Phase 2 bryostatin 1;paclitaxel
23 Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel Completed NCT00003087 Phase 2 cisplatin;paclitaxel
24 An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
25 A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
26 Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens Completed NCT00009880 Phase 2 cisplatin;fluorouracil;paclitaxel
27 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
28 Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer Completed NCT00381706 Phase 2 ECF;IC;FOLFOX
29 A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia Completed NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
30 Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia Completed NCT00938470 Phase 2 capecitabine;docetaxel;fluorouracil;oxaliplatin
31 Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus Completed NCT00033657 Phase 2 cisplatin;irinotecan hydrochloride;paclitaxel
32 Paclitaxel Combined With 5-FU and Cisplatin Concomitant With Radiotherapy in the Management of Locally Advanced or Metastatic Esophageal Cancer (Adenocarcinoma and Squamous Histologies) - A Phase I/Modified Phase II Trial Completed NCT00002984 Phase 1, Phase 2 cisplatin;fluorouracil;paclitaxel
33 INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL Recruiting NCT02205047 Phase 2 Cisplatin;5-fluorouracil or Capecitabine;Trastuzumab;Pertuzumab
34 Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Recruiting NCT02735239 Phase 1, Phase 2 Durvalumab;Tremelimumab;Oxaliplatin;Capecitabine;Paclitaxel;Carboplatin
35 Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial) Recruiting NCT03399071 Phase 2 FLOT-A
36 A Phase II Trial Evaluating the Effectiveness of Itraconazole in Improving Pathologic Complete Response Rates in Patients With Esophageal Cancer Through Inhibition of the Hedgehog and AKT Signaling Pathways Recruiting NCT04018872 Phase 2 Itraconazole
37 A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer Active, not recruiting NCT01498289 Phase 2 FOLFOX regimen;docetaxel;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
38 Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus Suspended NCT00048529 Phase 2 T900607-sodium intravenous
39 Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab Terminated NCT00827671 Phase 2 cetuximab
40 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
41 PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project Terminated NCT00004897 Phase 2 cisplatin;fluorouracil;hydroxyurea;leucovorin calcium
42 Effect of Zinc on Barrett's Metaplasia Unknown status NCT01984580 Phase 1 zinc gluconate
43 A Pilot Study of Tamoxifen in Oesophageal Cancer Unknown status NCT02513849 Phase 1 Tamoxifen
44 A Pilot Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus Completed NCT01238042 Phase 1 HPPH
45 Phase I Trial of Combined Modality Irinotecan, Cisplatin, and Concurrent Radiation Therapy for Patients With Locally Advanced Esophageal Cancer Completed NCT00005638 Phase 1 cisplatin;irinotecan hydrochloride
46 A Phase I Study of Oxaliplatin in Combination With Continuous Infusion 5-Fluorouracil and Radiation in Esophageal Cancer Completed NCT00004257 Phase 1 fluorouracil;oxaliplatin
47 A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL Completed NCT00002711 Phase 1 chemotherapy;cisplatin;paclitaxel
48 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
49 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
50 A Phase I Trial of Irinotecan, Radiation Therapy and Escalating Doses of Docetaxel With Cisplatin in Locally Advanced Esophageal Cancer Completed NCT00601692 Phase 1 cisplatin;docetaxel;irinotecan hydrochloride

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

41
Liver, Bone, Testes, T Cells, Lung, Breast, Lymph Node

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show top 50) (show all 90)
# Title Authors PMID Year
1
MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. 88
20301167 2010
2
Allergies and the Subsequent Risk of Cancer among Elderly Adults in the United States. 38
30700443 2019
3
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. 38
31036088 2019
4
Desmoplasia and Detached Papillae in Early Esophageal Adenocarcinoma: A Histologic Study on Endoscopic Submucosal Dissection Specimens. 38
31019616 2019
5
A six-microRNA signature can better predict overall survival of patients with esophagus adenocarcinoma. 38
31380150 2019
6
Barrett's Esophagus in Patients with Gastroesophageal Reflux Disease. 38
29983427 2018
7
Obesity and Cancer: Evidence, Impact, and Future Directions. 38
29038151 2018
8
The arachidonic acid metabolism protein-protein interaction network and its expression pattern in esophageal diseases. 38
29636881 2018
9
Histopathological Assessment for Esophageal Adenocarcinoma. 38
29600360 2018
10
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. 38
28488526 2017
11
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. 38
28184414 2017
12
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. 38
27636117 2017
13
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. 38
28049580 2017
14
Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features. 38
28393072 2017
15
The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. 38
28243118 2017
16
Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma. 38
28744358 2017
17
[The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus]. 38
30615323 2016
18
Detection of human papillomavirus DNA in gastric carcinoma specimens in a high-risk region of Iran. 38
27588180 2016
19
Trajectory of body shape across the lifespan and cancer risk. 38
26704725 2016
20
Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus. 38
26504043 2015
21
Simultaneous Esophageal Squamous Cell Carcinoma and Adenocarcinoma: A Case Report. 38
26609356 2015
22
Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma. 38
25952408 2015
23
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. 38
25947566 2015
24
Analysis of AC3-33 gene expression in multiple organ cancer and adjacent normal tissue by RNA in situ hybridization. 38
26137149 2015
25
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. 38
24708360 2015
26
Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. 38
24869991 2015
27
Prolonged Impacted Denture in the Esophagus: A Case Report and Review of the Literature. 38
27162898 2015
28
Unusual metastasis of esophageal cancer. 38
25518280 2014
29
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? 38
26185881 2014
30
Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. 38
24519530 2014
31
OCT3 and SOX2 promote the transformation of Barrett's esophagus to adenocarcinoma by regulating the formation of tumor stem cells. 38
24481676 2014
32
Radiotherapy in the multimodality management of esophageal cancer. 38
25799618 2014
33
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. 38
23434259 2013
34
MUTYH association with esophageal adenocarcinoma in a Han Chinese population. 38
24377542 2013
35
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. 38
22875307 2013
36
Aberrant expression of Wnt and Notch signal pathways in Barrett's esophagus. 38
22889748 2012
37
Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. 38
21951971 2012
38
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). 38
22467322 2012
39
Endoscopic imaging in Barrett's esophagus: current practice and future applications. 38
24714225 2012
40
Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. 38
22509480 2012
41
Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. 38
22057498 2011
42
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. 38
21166737 2011
43
Does impaired gallbladder function contribute to the development of Barrett's esophagus and esophageal adenocarcinoma? 38
21484485 2011
44
Significance of platelet count in esophageal carcinomas. 38
21372352 2011
45
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers. 38
20565814 2010
46
Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. 38
20676880 2010
47
Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis. 38
19394011 2009
48
[Chemoprevention of Barrett's esophagus by celecoxib in rats]. 38
19830863 2009
49
Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study. 38
19272137 2009
50
[Review of the association between obesity and gastroesophageal reflux and its complications]. 38
19250782 2009

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 TP53 SMAD4 PTGS2
2 11.66 TP53 PTGS2 MIR215 MIR21 MIR145 MIR143
3 11.49 TP53 SMAD4 ERBB2
4 11.04 TP53 SMAD4 PTGS2
5 10.79 SMAD4 MIR145 GATA6

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.85 TP53 SMAD4 PTGS2 MIR21
2 positive regulation of protein kinase B signaling GO:0051897 9.74 MIR21 MIR143 ERBB2
3 positive regulation of angiogenesis GO:0045766 9.71 MIR21 MIR143 GATA6
4 cellular response to hypoxia GO:0071456 9.67 TP53 PTGS2 GATA6
5 negative regulation of angiogenesis GO:0016525 9.65 MIR21 MIR145 MIR143
6 negative regulation of apoptotic process GO:0043066 9.62 TP53 PTGS2 MIR21 GATA6
7 regulation of ERK1 and ERK2 cascade GO:0070372 9.59 MIR145 ERBB2
8 positive regulation of cell cycle arrest GO:0071158 9.58 TP53 GATA6
9 outflow tract septum morphogenesis GO:0003148 9.58 SMAD4 GATA6
10 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.56 MIR21 MIR143
11 regulation of smooth muscle contraction GO:0006940 9.52 MIR145 MIR143
12 cellular sodium ion homeostasis GO:0006883 9.51 ATP4A ATP12A
13 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.46 ATP4A ATP12A
14 sodium ion export across plasma membrane GO:0036376 9.43 ATP4A ATP12A
15 cellular potassium ion homeostasis GO:0030007 9.4 ATP4A ATP12A
16 angiotensin-activated signaling pathway GO:0038166 9.37 MIR145 MIR143
17 aorta smooth muscle tissue morphogenesis GO:0060414 9.26 MIR145 MIR143
18 regulation of phenotypic switching GO:1900239 9.16 MIR145 MIR143
19 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR145 MIR143
20 negative regulation of cardiac muscle hypertrophy GO:0010614 8.8 SMAD4 MIR21 MIR145

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0016702 9.16 PTGS2 CDO1
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP4A ATP12A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP4A ATP12A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....